• 亿邦公众号
    • APP下载

新一代双靶点阿尔茨海默病创新药 全网独家授权在阿里健康正品首发

作者:龚作仁 文章来源:Laborer

2026-11-20 11:38

作者:龚作仁 文章来源:Laborer

2026-11-20 11:38

邦小白快读

EN
全文速览

总1:这款药的基本信息和购药方式值得关注。

1. 11月18日,通化金马生产的1类创新药琥珀酸安维吖啶片(商品名耄安通®)在阿里健康B2C与闪购同步首发,阿里健康获独家授权,成为线上独家首发平台及正规线上销售渠道,强调正品保障。

2. 该药用于轻、中度阿尔茨海默病,是国内首个自主研发的新一代AD治疗药物,采用双胆碱酯酶抑制机制,Ⅲ期及延长期研究显示在认知功能、日常生活能力和临床总体印象方面有积极结果,安全性和依从性较好。

3. 11月15日首次纳入国家医保目录,从6月获批到进医保不足半年,有望降低用药负担。

总2:买药可按需求选渠道。

1. 远场B2C依托自营大药房和全国仓配网络,适合线上购药和长期用药;近场闪购依托即时零售、就近履约和即时配送,适合及时购药。

2. 阿里健康有药师随访、患者社群、在线复诊等慢病管理服务,可帮助长病程患者咨询和随访。

总1:这款国产AD创新药的品牌与渠道打法有参考价值。

1. 品牌营销上,通化金马产品耄安通®借阿里健康“新特药线上首发阵地”全网独家授权首发,强化正规线上渠道和正品保障心智。

2. 渠道建设上,采用远场B2C与近场闪购全域上线:B2C依托自营大药房和全国仓配网络承接长期用药,闪购以即时零售、就近履约和即时配送承接及时购药。

3. 产品研发上,该药为国内首个自主研发的轻、中度AD新一代药物,采用双胆碱酯酶抑制机制和全新化学结构,Ⅲ期及延长期研究显示积极结果,安全性和依从性较好。

总2:支付与用户运营影响品牌放量。

1. 11月15日首次纳入国家医保目录,从6月获批到进医保不足半年,有助于降低患者负担、扩大受益人群。

2. 面向AD长病程用户,阿里健康以药师随访、患者社群、在线复诊和慢病管理团队提供服务,品牌可把首发延伸到整个治疗周期,提升依从性。

总1:新品、医保和全域渠道带来经营机会。

1. 11月18日,通化金马1类创新药耄安通®在阿里健康B2C与闪购同步首发,阿里健康获线上独家首发及正规销售渠道授权,强调正品保障。

2. 该药用于轻、中度AD,是国内首个自主研发的新一代药物,采用双胆碱酯酶抑制机制,Ⅲ期及延长期研究在认知、日常生活能力和临床总体印象方面有积极结果,安全性和依从性较好。

3. 11月15日首次纳入国家医保目录,从6月获批到进医保不足半年,有望降低患者负担、扩大受益人群。

总2:可学习B2C加闪购协同与慢病管理。

1. 远场B2C适合线上购药和长期用药,近场闪购适合及时购药,二者按患者用药安排协同。

2. 阿里健康携手上百家药企共建慢病管理服务体系,组建近百人慢病管理团队与200人全职药师团队,通过药师随访、患者社群、在线复诊改善依从性。

3. 需关注稳定供应、购药便利性和配送效率等实际问题的解决。

总1:生产端与产品端都有可关注信息。

1. 耄安通®由通化金马生产,是1类创新药,用于轻、中度AD治疗,为国内首个自主研发的新一代AD药物,说明生产主体和产品定位明确。

2. 产品采用双胆碱酯酶抑制机制,可逆性抑制乙酰胆碱酯酶和丁酰胆碱酯酶,增加脑内胆碱能突触间隙乙酰胆碱浓度;具有全新化学结构,Ⅲ期及延长期研究在认知功能、日常生活能力和临床总体印象方面有积极结果,安全性和依从性较好。

总2:商业机会与数字化电商启示较直接。

1. 11月18日在阿里健康B2C与闪购同步首发,且获线上独家授权,配合11月15日首次纳入国家医保目录,产品可及性和受益人群有望提升。

2. 远场B2C依托自营大药房和全国仓配网络,近场闪购依靠就近履约和即时配送,工厂可理解线上线下协同、稳定供应和配送效率对创新药上量的重要性。

3. 平台还提供药师随访、患者社群、在线复诊等慢病管理服务,提示产品供应之外还需配合长周期用药管理。

总1:AD创新药的服务需求正从首发延伸到全周期。

1. 耄安通®为国内首个自主研发的轻、中度AD新一代药物,采用双胆碱酯酶抑制机制,具有全新化学结构,Ⅲ期及延长期研究在认知功能、日常生活能力、临床总体印象方面有积极结果,安全性和依从性较好。

2. 11月18日该药在阿里健康B2C与闪购同步首发,阿里健康获线上独家首发及正规销售渠道授权,正品保障和全域渠道成为服务入口。

总2:客户痛点与解决方案较清晰。

1. AD患者认知功能下降并影响日常生活能力,给家庭带来长期照护负担;药品上市后还面临稳定供应、购药便利性和配送效率问题。

2. 阿里健康以远场B2C满足长期用药,以近场闪购满足及时购药,二者协同。

3. 平台携手上百家药企共建慢病管理服务体系,组建近百人慢病管理团队与200人全职药师团队,通过药师随访、患者社群、在线复诊提供教育、咨询与随访,改善用药依从性。

总1:平台在创新药首发与全域履约上形成新做法。

1. 阿里健康获耄安通®线上独家首发平台及正规线上销售渠道授权,11月18日B2C与闪购同步首发,强调正品保障。

2. 平台以远场B2C的自营大药房和全国仓配网络满足长期用药;以近场闪购的即时零售、就近履约和即时配送满足及时购药,两种服务协同。

3. 该药为国内首个自主研发的轻、中度AD新一代药物,采用双胆碱酯酶抑制机制和全新化学结构,Ⅲ期及延长期研究显示积极结果,安全性和依从性较好;11月15日首次纳入国家医保目录。

总2:招商与运营管理可落到慢病服务体系。

1. 阿里健康作为“新特药线上首发阵地”,携手上百家药企共建慢病管理服务体系,组建近百人慢病管理团队与200人全职药师团队,通过药师随访、患者社群、在线复诊服务长病程患者。

2. 平台需关注稳定供应、购药便利性、配送效率和用药依从性等问题,以正规渠道和正品保障规避风险。

总1:AD创新药产业出现研发、准入与渠道联动的新动向。

1. 耄安通®是通化金马生产的1类创新药,用于轻、中度AD,为国内首个自主研发的新一代AD治疗药物;采用双胆碱酯酶抑制机制,可逆性抑制乙酰胆碱酯酶和丁酰胆碱酯酶,增加脑内胆碱能突触间隙乙酰胆碱浓度,具有全新化学结构。

2. Ⅲ期及延长期研究显示,药物在改善认知功能、日常生活能力和临床总体印象方面取得积极结果,安全性和依从性较好。

3. 该药6月获批,11月15日首次纳入国家医保目录,前后不足半年,体现创新药准入与医保衔接的速度。

总2:线上首发与慢病管理形成可观察的商业模式。

1. 11月18日阿里健康B2C与闪购同步首发,并获线上独家首发及正规销售渠道授权;远场B2C承接长期用药,近场闪购承接及时购药。

2. 平台携手上百家药企共建慢病管理服务体系,组建近百人慢病管理团队与200人全职药师团队,通过药师随访、患者社群、在线复诊改善依从性。

3. 仍需研究稳定供应、购药便利性、配送效率和长周期照护负担等新问题。

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

Summary 1: The drug's basic information and purchasing options are worth noting.

1. On November 18, Anweiyading succinate tablets (brand name Maoantong®), a Class 1 innovative drug produced by Tonghua Jinma, launched simultaneously on Alibaba Health's B2C and flash-purchase channels. Alibaba Health obtained exclusive authorization, becoming the exclusive online launch platform and an authorized online sales channel, with an emphasis on authentic-product assurance.

2. The drug is indicated for mild to moderate Alzheimer's disease and is China's first self-developed next-generation AD therapy. It uses a dual cholinesterase inhibition mechanism. Phase III and extension studies showed positive results in cognitive function, activities of daily living, and overall clinical impression, with good safety and adherence.

3. On November 15, it was included in the national medical insurance directory for the first time, less than six months after approval in June, which is expected to reduce the medication burden.

Summary 2: Purchasing channels can be selected based on need.

1. Far-field B2C relies on self-operated pharmacies and a nationwide warehousing and distribution network, suitable for online purchasing and long-term medication; near-field flash purchase relies on instant retail, nearby fulfillment, and immediate delivery, suitable for timely purchases.

2. Alibaba Health offers chronic disease management services such as pharmacist follow-up, patient communities, and online follow-up consultations, which can help patients with long disease courses obtain advice and follow-up.

Summary 1: The brand and channel strategy for this domestically developed AD innovative drug offers useful reference value.

1. In brand marketing, Tonghua Jinma's Maoantong® used Alibaba Health's position as a "online launch venue for new and specialty drugs" for an exclusive network-wide authorized launch, strengthening awareness of authorized online channels and authentic-product assurance.

2. In channel building, it adopts full-domain launch through far-field B2C and near-field flash purchase: B2C uses self-operated pharmacies and a nationwide warehousing and distribution network to serve long-term medication, while flash purchase uses instant retail, nearby fulfillment, and immediate delivery to serve timely medication.

3. In product R&D, the drug is China's first self-developed next-generation therapy for mild to moderate AD, using a dual cholinesterase inhibition mechanism and a novel chemical structure. Phase III and extension studies showed positive results, with good safety and adherence.

Summary 2: Payment and user operations affect brand scale-up.

1. On November 15, it was included in the national medical insurance directory for the first time, less than six months after approval in June, helping reduce patient burden and expand the beneficiary population.

2. For long-course AD users, Alibaba Health provides pharmacist follow-up, patient communities, online follow-up consultations, and chronic disease management teams. Brands can extend the launch into the entire treatment cycle to improve adherence.

Summary 1: New products, medical insurance, and full-domain channels bring business opportunities.

1. On November 18, Tonghua Jinma's Class 1 innovative drug Maoantong® launched simultaneously on Alibaba Health's B2C and flash-purchase channels. Alibaba Health obtained authorization as the exclusive online launch platform and authorized sales channel, with an emphasis on authentic-product assurance.

2. The drug is indicated for mild to moderate AD and is China's first self-developed next-generation therapy. It uses a dual cholinesterase inhibition mechanism. Phase III and extension studies showed positive results in cognition, activities of daily living, and overall clinical impression, with good safety and adherence.

3. On November 15, it was included in the national medical insurance directory for the first time, less than six months after approval in June, expected to reduce patient burden and expand the beneficiary population.

Summary 2: Sellers can learn from B2C plus flash-purchase coordination and chronic disease management.

1. Far-field B2C is suitable for online purchasing and long-term medication, while near-field flash purchase is suitable for timely medication; the two coordinate according to patients' medication schedules.

2. Alibaba Health works with hundreds of pharmaceutical companies to build a chronic disease management service system, forming a chronic disease management team of nearly 100 people and a full-time pharmacist team of 200 people, improving adherence through pharmacist follow-up, patient communities, and online follow-up consultations.

3. Attention should be paid to solving practical issues such as stable supply, purchasing convenience, and delivery efficiency.

Summary 1: There is noteworthy information on both the production and product sides.

1. Maoantong® is produced by Tonghua Jinma. It is a Class 1 innovative drug for the treatment of mild to moderate AD and is China's first self-developed next-generation AD drug, indicating a clear manufacturing entity and product positioning.

2. The product uses a dual cholinesterase inhibition mechanism, reversibly inhibiting acetylcholinesterase and butyrylcholinesterase to increase acetylcholine concentration in the cholinergic synaptic space in the brain. It has a novel chemical structure. Phase III and extension studies showed positive results in cognitive function, activities of daily living, and overall clinical impression, with good safety and adherence.

Summary 2: Commercial opportunities and digital e-commerce implications are relatively direct.

1. On November 18, it launched simultaneously on Alibaba Health's B2C and flash-purchase channels and obtained exclusive online authorization. Combined with its first inclusion in the national medical insurance directory on November 15, product accessibility and the beneficiary population are expected to increase.

2. Far-field B2C relies on self-operated pharmacies and a nationwide warehousing and distribution network, while near-field flash purchase relies on nearby fulfillment and immediate delivery. Factories can understand the importance of online-offline coordination, stable supply, and delivery efficiency for scaling innovative drugs.

3. The platform also provides chronic disease management services such as pharmacist follow-up, patient communities, and online follow-up consultations, suggesting that beyond product supply, long-cycle medication management is also needed.

Summary 1: Service demand for AD innovative drugs is extending from launch to the full cycle.

1. Maoantong® is China's first self-developed next-generation therapy for mild to moderate AD. It uses a dual cholinesterase inhibition mechanism and has a novel chemical structure. Phase III and extension studies showed positive results in cognitive function, activities of daily living, and overall clinical impression, with good safety and adherence.

2. On November 18, the drug launched simultaneously on Alibaba Health's B2C and flash-purchase channels. Alibaba Health obtained authorization as the exclusive online launch platform and authorized sales channel, making authentic-product assurance and full-domain channels service entry points.

Summary 2: Customer pain points and solutions are relatively clear.

1. AD patients experience declining cognitive function that affects activities of daily living, placing a long-term care burden on families. After launch, the drug also faces issues such as stable supply, purchasing convenience, and delivery efficiency.

2. Alibaba Health uses far-field B2C to meet long-term medication needs and near-field flash purchase to meet timely medication needs, with the two coordinated.

3. The platform works with hundreds of pharmaceutical companies to build a chronic disease management service system, forming a chronic disease management team of nearly 100 people and a full-time pharmacist team of 200 people. It provides education, consultation, and follow-up through pharmacist follow-up, patient communities, and online follow-up consultations to improve medication adherence.

Summary 1: The platform has developed new practices in innovative drug launches and full-domain fulfillment.

1. Alibaba Health obtained authorization as the exclusive online launch platform and authorized online sales channel for Maoantong®. On November 18, it launched simultaneously on B2C and flash purchase, with an emphasis on authentic-product assurance.

2. The platform uses far-field B2C's self-operated pharmacies and nationwide warehousing and distribution network to meet long-term medication needs; it uses near-field flash purchase's instant retail, nearby fulfillment, and immediate delivery to meet timely medication needs, with the two services coordinated.

3. The drug is China's first self-developed next-generation therapy for mild to moderate AD, using a dual cholinesterase inhibition mechanism and a novel chemical structure. Phase III and extension studies showed positive results, with good safety and adherence; on November 15, it was included in the national medical insurance directory for the first time.

Summary 2: Merchant recruitment and operational management can be grounded in the chronic disease service system.

1. As an "online launch venue for new and specialty drugs," Alibaba Health works with hundreds of pharmaceutical companies to build a chronic disease management service system, forming a chronic disease management team of nearly 100 people and a full-time pharmacist team of 200 people, serving long-course patients through pharmacist follow-up, patient communities, and online follow-up consultations.

2. The platform needs to address issues such as stable supply, purchasing convenience, delivery efficiency, and medication adherence, while using authorized channels and authentic-product assurance to mitigate risks.

Summary 1: New dynamics linking R&D, market access, and channels are emerging in the AD innovative drug industry.

1. Maoantong® is a Class 1 innovative drug produced by Tonghua Jinma for mild to moderate AD and is China's first self-developed next-generation AD therapy. It uses a dual cholinesterase inhibition mechanism, reversibly inhibiting acetylcholinesterase and butyrylcholinesterase to increase acetylcholine concentration in the cholinergic synaptic space in the brain, and has a novel chemical structure.

2. Phase III and extension studies showed positive results in improving cognitive function, activities of daily living, and overall clinical impression, with good safety and adherence.

3. The drug was approved in June and first included in the national medical insurance directory on November 15, less than six months apart, reflecting the speed of connection between innovative drug market access and medical insurance.

Summary 2: Online launch and chronic disease management form an observable business model.

1. On November 18, Alibaba Health's B2C and flash-purchase channels launched it simultaneously, and it obtained authorization as the exclusive online launch platform and authorized sales channel; far-field B2C serves long-term medication, while near-field flash purchase serves timely medication.

2. The platform works with hundreds of pharmaceutical companies to build a chronic disease management service system, forming a chronic disease management team of nearly 100 people and a full-time pharmacist team of 200 people, improving adherence through pharmacist follow-up, patient communities, and online follow-up consultations.

3. New issues such as stable supply, purchasing convenience, delivery efficiency, and long-cycle care burden still require research.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

11月18日,通化金马生产的1类创新药琥珀酸安维吖啶片(商品名:耄安通®)在阿里健康B2C与闪购渠道同步首发。经独家授权,阿里健康成为该药线上独家首发平台及正规线上销售渠道,为患者提供正品保障。该药是国内首个自主研发的用于轻、中度阿尔茨海默病(AD)治疗的新一代药物,此次上线将进一步提升AD创新治疗药物的可及性。

AD是一种进行性神经退行性疾病,患者会逐渐出现记忆力、语言能力、判断能力等认知功能下降,病情进展还可能影响日常生活能力,给患者及家庭带来长期照护负担。药物研发和治疗选择的增加,为患者带来了新的希望。与此同时,药品获批上市后,如何保障稳定供应、提升购药便利性和配送效率,也是患者获取药物过程中需要考虑的实际问题。

目前,乙酰胆碱酯酶抑制剂类药物仍是AD领域的基础治疗用药。耄安通®琥珀酸安维吖啶片则采用双胆碱酯酶抑制机制,可逆性抑制乙酰胆碱酯酶和丁酰胆碱酯酶对乙酰胆碱、丁酰胆碱的水解,增加脑内胆碱能突触间隙中的乙酰胆碱浓度,增强胆碱能神经功能。

该药具有全新的化学结构,其Ⅲ期临床研究及延长期研究显示,药物在改善患者认知功能、日常生活能力和临床总体印象方面取得积极结果,研究期间表现出较好的安全性和依从性。另悉,耄安通®已于11月15日首次纳入国家医保目录。从今年6月获批到进入医保目录,前后不足半年。纳入医保将有助于降低患者用药负担、扩大受益人群。

此次,耄安通®在阿里健康“B2C+闪购”全域上线,进一步丰富了平台在AD治疗领域的创新药供给。其中,远场B2C依托自营大药房及全国仓配网络,满足患者线上购药和长期用药需求;近场闪购则发挥即时零售优势,通过就近履约和即时配送,满足患者及时购药需求。两种服务相互协同,AD患者可以结合自身用药安排和实际需求,选择相应的购药方式。

AD治疗是一场以年为单位的长跑,作为"新特药线上首发阵地",阿里健康在首发之外持续承接的,正是这条长周期的管理线:平台携手上百家药企共建慢病管理服务体系,组建近百人的慢病管理团队与200人的全职药师团队,通过药师随访、患者社群、在线复诊等方式,为长病程患者提供教育、咨询与随访服务,改善用药依从性。依托这样的能力底座,耄安通®的全域首发,也让这款国产创新药的可及性支持从上线延伸到整个治疗周期。

注:文/龚作仁,文章来源:Laborer,本文为作者独立观点,不代表亿邦动力立场。

【版权提示】亿邦动力倡导尊重与保护知识产权。未经许可,任何人不得复制、转载、或以其他方式使用本网站的内容。如发现本站文章存在版权问题,烦请提供版权疑问、身份证明、版权证明、联系方式等发邮件至run@ebrun.com,我们将及时沟通与处理。

已点赞

+1

{{ praise_text }}

好文章,值得被更多人看到

FAQ回顾

耄安通(琥珀酸安维吖啶片)是什么药?

耄安通(通用名:琥珀酸安维吖啶片)是通化金马生产的1类创新药,也是国内首个自主研发、用于轻中度阿尔茨海默病(AD)治疗的新一代药物,具有全新化学结构,采用双胆碱酯酶抑制机制。该药2026年6月获批,同年11月15日首次纳入国家医保目录。

阿尔茨海默病治疗中的双胆碱酯酶抑制机制是什么?

双胆碱酯酶抑制机制是指可逆性地抑制乙酰胆碱酯酶和丁酰胆碱酯酶对乙酰胆碱、丁酰胆碱的水解,从而增加脑内胆碱能突触间隙中的乙酰胆碱浓度,增强胆碱能神经功能。目前乙酰胆碱酯酶抑制剂类药物仍是AD领域的基础治疗用药,而耄安通在此机制上做了双重抑制设计。

正品耄安通可以在哪里买到?线上购药有哪些方式?

阿里健康是该药的线上独家首发平台及正规线上销售渠道,2026年11月18日在B2C与闪购渠道同步首发。远场B2C依托自营大药房及全国仓配网络,满足长期用药需求;近场闪购通过就近履约和即时配送,满足及时购药需求,患者可按用药安排选择。

阿尔茨海默病患者长期用药的管理和依从性问题如何解决?

阿里健康携手上百家药企共建慢病管理服务体系,组建近百人的慢病管理团队与200人的全职药师团队,通过药师随访、患者社群、在线复诊等方式,为长病程患者提供教育、咨询与随访服务,帮助改善用药依从性,使可及性支持延伸至整个治疗周期。

创新药纳入国家医保目录对AD患者有什么影响?

耄安通于2026年11月15日首次纳入国家医保目录,从当年6月获批到进入医保目录不足半年。纳入医保有助于降低患者用药负担、扩大受益人群,配合线上B2C与闪购渠道的全域供给,可进一步提升AD创新治疗药物的可及性。

广告

下一篇

跨境电商资源对接

《全球跨境电商服务商资源手册》第二期手册现已发布,触达更多资源,了解跨境服务商信息,欢迎点击链接下载。

了解详情

千峰对话芯化和云王征博士:产业互联网正处在一次模态切换的当口

产业互联网正迎来从「数据+交易」向「数据×Agent×跨境履约」的模态切换。近日,亿邦动力董事长、亿邦智库院长郑敏与芯化和云创始人兼CEO王征博士展开深度对话。